Avicanna Inc. is a sponsor at the Benzinga Cannabis Capital Conference set to take place on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
After a pivotal 2020 recreational and medical cannabis products are thriving at a speed that will continue through 2021. Cannabis stocks are rising, positive political changes worldwide are happening, and sales are hitting all-time highs. In fact, according to Prohibition Partners, legal cannabis sales in North America reached $18.1billion in 2020 and are projected to rise to $39.1 billion by 2025.
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) is a Canadian vertically-integrated biopharmaceutical company of plant-derived cannabinoid-based products. The company showed resilience throughout 2020 and is paving the way to achieve sustainability and profitability in 2021. From new launches to partnerships, Avicanna is achieving new milestones. Here’s what you need to know.
Driving Biopharmaceutical Advancements
Avicanna launched 4.5 years ago as a multinational company with an international footprint in the USA, Canada, Latin America, and Europe. Since inception, the company’s mission has been to provide patients and consumers with advanced formulations of cannabinoids backed by scientific rigor and clinical evidence.
It provides the global marketplace with advanced natural…
